TrialAlimentary pharmacology & therapeutics2019

Long-term safety and tolerability of oral tofacitinib in patients with Crohn's disease: results from a phase 2, open-label, 48-week extension study.

Julián Panés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.